T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Latest Information Update: 12 Mar 2024
At a glance
- Drugs KYV-101 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
Most Recent Events
- 07 Mar 2024 According to a Kyverna Therapeutics media release, results of this trial were published by the NIH in Nature Medicine.
- 23 May 2023 New trial record